Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer

ESMO 2016

7 - 11 Oct 2016

Published: 8 Oct 2016

Views: 4979

Rating:

Save

Prof John Robertson - University of Nottingham, Nottingham, UK

Prof Robertson speaks with ecancer at ESMO 2016 about the results of the phase III FALCON trial, which found fulvestrant significantly increased progression-free survival (PFS) in women with hormone-receptor-positive advanced breast cancer, and particularly those with less aggressive lower-volume disease.

He outlines the research that led to this trial, as discussed at SABCS 2014, and explains what these results mean for care going forwards

These results were also discussed by Dr Matthew Ellis, who spoke with ecancer here.

Read the news story for more.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients

Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

Prof Dennis Slamon - UCLA, Los Angeles, USA

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients ( Prof Dennis Slamon - UCLA, Los Angeles, USA )

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

More from ecancer